M&A / Deals Oxford BioTherapeutics signs collaboration with Bristol Myers Squibb PharmaTimesPartnership to develop nextgeneration Tcell engagers for solid tumoursM&A / DealsRead full story pharminent April 9, 2026 (Last updated: April 9, 2026) PharmaTimes Partnership to develop nextgeneration Tcell engagers for solid tumours M&A / DealsRead full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Innovent’s CDMO gets green light to make biologics at large Chinese plantNext: Avalyn plots IPO to push inhaled pulmonary fibrosis pipeline through clinic Related Stories M&A / Deals Teva and Polpharma Biologics sign global deal for ocrelizumab biosimilar pharminent July 10, 2026 M&A / Deals GSK ends dementia alliance with Alector after setbacks pharminent July 9, 2026 M&A / Deals AstraZeneca, GSK intensify China ties with Sino Biopharm deals pharminent July 8, 2026
